• This analysis aimed to provide an update of 2014 and 2016 podium presentations by evaluating recent oncology-related HTA decisions and the associated rationale to identify trends in selected countries
OBJECTIVES
• HTA surveillance was conducted for oncology-related therapeutic agents, evaluating by primary site of origin, decision, and rationale for the decision -Decisions were categorized as favorable (defined as a decision that advances the product toward coverage or reimbursement), unfavorable (a decision that blocks/hinders coverage or reimbursement), or mixed (both favorable and unfavorable)
• Major resubmissions and multiple decisions on a single agent/disease from a country were counted as separate decisions -Surveillance was conducted from January 1, 2012 to April 30, 2018 (76 months) • Previously conducted analyses were presented via podium presentations in 2014 and 2016 -The rationale for each decision was examined to discern global trends in components of pharmaceutical product assessment and reimbursement
• HTA bodies assessed included: • While the number of HTA decisions for oncology agents has increased every 2 years from the beginning of this study, the number of favorable decisions has remained relatively consistent -There are more mixed decisions in recent years than in the first 2 years of the study ( • Of the decisions where public summary documents were available, most favorable decisions fell in the $45,000 to $75,000 incremental cost-effectiveness ratio (ICER) range -Many assessments were submitted on a cost-minimization basis; therefore, no ICER was reported -For both favorable and unfavorable decisions, PBAC often will provide a more general assessment of the model's certainty and most likely ICER instead of a specific range 
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Figure 6. Amelioration du Service Medical Rendu (ASMR; n=112)
Note that 3 ASMR values were unspecified.
• Only 5% (6/121) of decisions had insufficient medical value and were therefore not included on the list of reimbursable drugs -Favorability of decisions in France is highly dependent upon definition; if ASMR V were to be considered unfavorable, then the percentage of favorability would be the lowest of all studied countries (45/121; 37%)
• Mixed decisions had differing levels of medical value when evaluated across several key domains, including:
• Each 2-year period from January 2012 onward has seen an increased number of oncology-based HTA decisions, with the most common primary sites of origin being breast, NSCLC, and melanoma
• Despite the perception of increased scrutiny by HTA agencies, when considering the most recent 76 months of oncology-related HTAs, two-thirds (66%) have been favorable -France (85%) and Canada (79%) have the highest percentage of favorable decisions, though nearly all Canadian approvals are dependent upon the cost-effectiveness being reduced to an appropriate level
• Because of the level of complexity in cancer treatment, oncology HTAs are often nuanced and consider aspects like patient performance status, line of therapy, and tumor expression
• For countries that consider cost-effectiveness (Australia, Canada, UK), economic model uncertainty and ICER confidence are key to decision favorability
• HTA agencies continue to employ mixed decisions based on subpopulations or decisions dependent upon reducing cost-effectiveness, which enhances the importance of developing strong health economic and clinical data
• Robust evidence proving unmet need, efficacy and safety, and cost-effectiveness is critical to achieving a favorable HTA decision across multiple major markets • Compared with other countries, Germany more commonly produces mixed decisions in which GBA-defined patient subgroups receive different levels of added benefit -Typically, specific evidence for patient subgroups is required for any level of added benefit, and without this evidence, there will be no proof of added benefit (ie, an unfavorable decision)
CONCLUSIONS
• The extent and probability of added benefit was often due to a presence or lack of added benefit (eg, inappropriate comparator or trial duration was too short to show benefit) in the targeted patient population, even if divided into subindications • Due to recent changes to the Cancer Drugs Fund (CDF) program, NICE reviews all therapies expected to receive marketing authorization for an oncology indication -As a result, a relatively high number of oncologic agents have been reviewed by NICE since the program change, which now provides a pathway to be "recommended for use within the CDF" if there is potential for a positive recommendation but remaining clinical uncertainty
RESULTS (cont.)
Number is equal to the number of decisions assessed within each time period.
United Kingdom
*Although the final assessment of added benefit is provided by the Federal Joint Committee (G-BA), this study examined the technology assessments conducted by IQWiG.
